Liu Yong-Mei, Wu Zhi-Kui, Chai Li-Min, Zhang Xin-Hua
Department of Molecular Biology, Guang'anmen Hospital, China Academy of Traditional Chinese Medicine, Beijing 100053, China.
Zhong Xi Yi Jie He Xue Bao. 2006 May;4(3):247-50. doi: 10.3736/jcim20060305.
To evaluate the effects of Yisui Shengxue Granules on expressions of alpha-hemoglobin stabilizing protein (AHSP) and erythroid transcription factor GATA-1 mRNAs in bone marrow of patients with beta-thalassemia, and to explore its possible molecular mechanism.
Twelve patients with beta-thalassemia intermedia were treated with Yisui Shengxue Granules for three months. The blood indexes including hemoglobin (Hb), RBC, fetal hemoglobin (HbF) and reticulated corpuscles (Ret) were examined before and after treatment. Total RNA was extracted from bone marrow karyocyte in 8 patients selected from these 12 patients before and after treatment, and the expression levels of the AHSP and GATA-1 mRNAs were measured by real-time PCR.
Yisui Shengxue Granules could not only obviously improve the clinical symptoms of patients with beta-thalassemia intermedia, but also obviously increased the contents of Hb, RBC, HbF and Ret (P<0.05, or P<0.01). The expression levels of AHSP and GATA-1 mRNAs also significantly increased after treatment as compared with those before treatment (P<0.05, or P<0.01).
The results revealed that one of the possible molecular mechanism of the effects caused by Yisui Shengxue Granules is that it can up-regulate the expression levels of AHSP and erythroid transcription factor GATA-1 mRNAs, enhance the protein synthesis of AHSP which can bind the relative excess free alpha-globin, prevent the formation of alpha -globin-cytotoxic precipitates in red blood cells and decrease the hemolysis.
评价益髓生血颗粒对β地中海贫血患者骨髓中α-血红蛋白稳定蛋白(AHSP)及红系转录因子GATA-1 mRNA表达的影响,探讨其可能的分子机制。
12例中间型β地中海贫血患者服用益髓生血颗粒3个月。治疗前后检测血红蛋白(Hb)、红细胞(RBC)、胎儿血红蛋白(HbF)和网织红细胞(Ret)等血液指标。从这12例患者中选取8例,分别在治疗前后提取骨髓有核细胞的总RNA,采用实时荧光定量PCR检测AHSP和GATA-1 mRNA的表达水平。
益髓生血颗粒不仅能明显改善中间型β地中海贫血患者的临床症状,还能显著提高Hb、RBC、HbF和Ret的含量(P<0.05或P<0.01)。与治疗前相比,治疗后AHSP和GATA-1 mRNA的表达水平也显著升高(P<0.05或P<0.01)。
结果表明,益髓生血颗粒发挥作用的可能分子机制之一是上调AHSP及红系转录因子GATA-1 mRNA的表达水平,增强AHSP的蛋白合成,后者可结合相对过量的游离α-珠蛋白,防止红细胞内α-珠蛋白细胞毒性沉淀物的形成,减少溶血。